Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:16 PM
Ignite Modification Date:
2025-12-24 @ 7:16 PM
NCT ID:
NCT06033703
Eligibility Criteria:
The primary rhegmatogenous detachment cohort will have the following selection criteria:
Inclusion criteria:
* Patients \> 18 years old
* Patients presenting for primary rhegmatogenous retinal detachment repair within 28 days of symptom onset
* Patients undergoing vitrectomy or vitrectomy with scleral buckle
Exclusion criteria:
* Patient unable to give consent
* Patient unable to follow-up
* Prior history of retinal detachment incisional surgery in presenting eye
* Prior history of open globe injury to presenting eye
* Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery, actively on glaucoma medication
* Prior history of corneal disease, or history of corneal edema
* Patient already on topical netarsudil in presenting eye
* Patient without natural lens or intraocular lens implant (I.e., aphakic patients)
* Patients with intraocular pressure \<8mm Hg in operative eye
* Active or chronic or recurrent uncontrolled ocular or systemic disease
* Active or history of chronic or recurrent inflammatory eye disease
* Diagnosis of proliferative diabetic retinopathy
* Signs of ocular infection at presentation in either eye
* Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively
* Inability to use/ apply topical eye drops
The proliferative vitreoretinopathy cohort will have the following selection criteria:
Inclusion criteria:
* Patients \> 18 years old
* Patient presenting with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma
* Patients undergoing vitrectomy or vitrectomy with scleral buckle
Exclusion criteria:
* Patient unable to give consent
* Patient unable to follow-up
* Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery
* Patient already on topical netarsudil in presenting eye
* Patients with intraocular pressure \<8mm Hg in operative eye
* Active or chronic or recurrent uncontrolled ocular or systemic disease
* Active or history of chronic or recurrent inflammatory eye disease
* Diagnosis of severe nonproliferative or proliferative diabetic retinopathy or vasoproliferative disease in operative eye
* Signs of ocular infection at presentation in either eye
* Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively
* Inability to use/ apply topical eye drops
* No Light Perception vision in operative eye
* Failure to achieve intraoperative reattachment
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06033703
Study Brief:
Protocol Section:
NCT06033703